JP2005526727A5 - - Google Patents

Download PDF

Info

Publication number
JP2005526727A5
JP2005526727A5 JP2003569178A JP2003569178A JP2005526727A5 JP 2005526727 A5 JP2005526727 A5 JP 2005526727A5 JP 2003569178 A JP2003569178 A JP 2003569178A JP 2003569178 A JP2003569178 A JP 2003569178A JP 2005526727 A5 JP2005526727 A5 JP 2005526727A5
Authority
JP
Japan
Prior art keywords
liposome
lipid
acid
active substance
spacer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2003569178A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005526727A (ja
Filing date
Publication date
Priority claimed from DE10207177A external-priority patent/DE10207177A1/de
Application filed filed Critical
Publication of JP2005526727A publication Critical patent/JP2005526727A/ja
Publication of JP2005526727A5 publication Critical patent/JP2005526727A5/ja
Abandoned legal-status Critical Current

Links

JP2003569178A 2002-02-19 2003-02-19 ｐＨ感受性カチオン脂質、それを含有するリポソーム及びナノカプセル Abandoned JP2005526727A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10207177A DE10207177A1 (de) 2002-02-19 2002-02-19 Fakultativ kationische Lipide
PCT/EP2003/001661 WO2003070220A1 (de) 2002-02-19 2003-02-19 Ph sensitiv kationische lipide, lipsomen und nanokapseln, die diese umfassen

Publications (2)

Publication Number Publication Date
JP2005526727A JP2005526727A (ja) 2005-09-08
JP2005526727A5 true JP2005526727A5 (enExample) 2006-04-06

Family

ID=27674784

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003569178A Abandoned JP2005526727A (ja) 2002-02-19 2003-02-19 ｐＨ感受性カチオン脂質、それを含有するリポソーム及びナノカプセル

Country Status (6)

Country Link
US (1) US8192753B2 (enExample)
EP (1) EP1480621A1 (enExample)
JP (1) JP2005526727A (enExample)
AU (1) AU2003210303A1 (enExample)
DE (1) DE10207177A1 (enExample)
WO (1) WO2003070220A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2487274A1 (en) * 2002-05-06 2003-11-13 Nucleonics Inc. Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent
JP2007520481A (ja) * 2004-01-15 2007-07-26 アルザ・コーポレーシヨン 治療薬を送達するためのリポソーム組成物
US20080088046A1 (en) * 2006-10-13 2008-04-17 Steffen Panzner Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome
EP1764091B1 (en) 2005-09-15 2017-08-30 Marina Biotech, Inc. Improvements in or relating to amphoteric liposomes
EP1948674A4 (en) 2005-11-02 2009-02-04 Protiva Biotherapeutics Inc MODIFIED SIRNA MOLECULES AND APPLICATIONS THEREOF
JP5122474B2 (ja) * 2005-12-01 2013-01-16 プロネイ・セラピューティクス・インコーポレイテッド 両性リポソーム製剤
KR101388320B1 (ko) 2005-12-15 2014-04-22 뽈리쁠뤼스-트랑스펙씨옹 양이온성 올리고뉴클레오티드, 이를 제조하기 위한 자동화방법 및 이의 용도
EP1844772A1 (en) 2006-04-06 2007-10-17 Polyplus-Transfection SA Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications
AU2007306556B2 (en) 2006-10-13 2014-04-10 Marina Biotech, Inc. Improvements in or relating to amphoteric liposomes
JP2010513354A (ja) * 2006-12-19 2010-04-30 ノヴォソム アクチェンゲゼルシャフト トランスフェクションエンハンサー要素を含む脂質および脂質集合体
US9006191B2 (en) 2007-12-27 2015-04-14 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering RNA
FR2926818B1 (fr) * 2008-01-30 2012-04-06 Centre Nat Rech Scient siRNA CATIONIQUES, SYNTHESE ET UTILISATION POUR L'ARN INTERFERENCE
WO2009129319A2 (en) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Silencing of csn5 gene expression using interfering rna
JP5588619B2 (ja) * 2009-03-11 2014-09-10 一丸ファルコス株式会社 ｐＨ応答性リポソーム
US20130017223A1 (en) 2009-12-18 2013-01-17 The University Of British Columbia Methods and compositions for delivery of nucleic acids
JP2013530187A (ja) 2010-06-17 2013-07-25 ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 炎症性疾患を治療するための組成物及び方法。
CN103153284B (zh) 2010-07-06 2015-11-25 诺华股份有限公司 含有其pKa值有利于RNA递送的脂质的脂质体
FI4005592T3 (fi) 2010-07-06 2023-01-13 Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille
PT3243526T (pt) 2010-07-06 2020-03-04 Glaxosmithkline Biologicals Sa Distribuição de arn para despoletar múltiplas vias imunitárias
US10487332B2 (en) 2010-07-06 2019-11-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
JP5911870B2 (ja) 2010-08-31 2016-04-27 ノバルティス アーゲー 免疫原をコードするｒｎａの送達のためのｐｅｇ化リポソーム
KR102266691B1 (ko) 2010-10-11 2021-06-23 노파르티스 아게 항원 전달 플랫폼
WO2012106490A1 (en) 2011-02-03 2012-08-09 The Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Multivalent vaccines for rabies virus and filoviruses
WO2012109495A1 (en) 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
US8789967B2 (en) 2011-06-02 2014-07-29 Musco Corporation Apparatus, method, and system for independent aiming and cutoff steps in illuminating a target area
JP2014522842A (ja) 2011-07-06 2014-09-08 ノバルティス アーゲー 免疫原性組み合わせ組成物およびその使用
WO2013032643A2 (en) * 2011-08-31 2013-03-07 Dicerna Pharmaceuticals, Inc. Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells
EP2780456A1 (en) 2011-11-17 2014-09-24 The U.S.A. as represented by the Secretary, Department of Health and Human Services Therapeutic rna switches compositions and methods of use
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
MX375442B (es) 2012-09-21 2025-03-06 Intensity Therapeutics Inc Un agente terapéutico y un agente mejorador de la permeación intracelular para usarse en el tratamiento de cáncer.
CN104884637A (zh) 2012-11-05 2015-09-02 普隆奈治疗公司 利用生物标志物通过bcl2表达的调节治疗癌症的方法
JP6339884B2 (ja) 2014-07-17 2018-06-06 富士フイルム株式会社 イミダゾール化合物およびそれを含有するリポソーム
US10415037B2 (en) 2014-10-02 2019-09-17 Arbutus Biopharma Corporation Compositions and methods for silencing hepatitis B virus gene expression
WO2016197132A1 (en) 2015-06-04 2016-12-08 Protiva Biotherapeutics Inc. Treating hepatitis b virus infection using crispr
CN108350455A (zh) 2015-07-29 2018-07-31 阿布特斯生物制药公司 用于使b型肝炎病毒基因表达沉默的组合物和方法
WO2017040702A1 (en) * 2015-08-31 2017-03-09 The Regents Of The University Of California Bipolar tetraether lipids
US12447166B2 (en) 2016-02-25 2025-10-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
EP3419629A4 (en) 2016-02-25 2019-10-30 Applied Biological Laboratories, Inc. COMPOSITIONS AND PROCEDURES FOR PROTECTION AGAINST AIRBORNE PATHOGENES AND IRRITATES
EP3439695B1 (en) 2016-04-04 2022-05-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Multivalent vaccines for rabies virus and coronaviruses
WO2018039131A1 (en) 2016-08-22 2018-03-01 Protiva Biotherapeutics, Inc. Anti-pd-1 antibodies, or fragments thereof, for treating hepatitis b
AU2017379901B2 (en) 2016-12-21 2024-02-15 Arbutus Biopharma Corporation Methods for ameliorating infusion reactions
US11198831B2 (en) 2019-01-31 2021-12-14 Kvi Llc Lubricant for a device
CA3174708A1 (en) 2020-03-04 2021-09-10 Verve Therapeutics, Inc. Compositions and methods for targeted rna delivery
EP4132951A4 (en) 2020-04-09 2025-06-11 Verve Therapeutics, Inc. CHEMICALLY MODIFIED GENE EDITING GUIDE RNAS WITH CAS12B
CN116234538A (zh) * 2021-03-09 2023-06-06 日本精化株式会社 磷脂
EP4380576A4 (en) 2021-08-03 2026-04-29 Verve Therapeutics Inc RNA TARGETED COMPOSITIONS AND ADMINISTRATION METHODS
CN115894281B (zh) * 2021-09-22 2025-07-01 广州谷森制药有限公司 阳离子脂质化合物、其制备方法、组合物及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE45744T1 (de) * 1984-07-25 1989-09-15 Ciba Geigy Ag Phosphatidylverbindungen, verfahren zu ihrer herstellung und ihre verwendung.
CA2032259A1 (en) * 1989-12-18 1991-06-19 Wayne J. Thompson Hiv protease inhibitors useful for the treatment of aids
JP2604268B2 (ja) * 1990-04-09 1997-04-30 富士写真フイルム株式会社 ペプチド誘導体両親媒性化合物、その中間体、ペプチド誘導体両親媒性化合物を用いたリポソームおよび薄膜
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
FR2701396B1 (fr) * 1993-02-12 1995-04-21 Oreal Procédé de stabilisation de vésicules de lipide(s) amphiphile(s) et composition pour application topique contenant lesdites vésicules stabilisées.
AU6044994A (en) * 1993-02-19 1994-09-14 Nippon Shinyaku Co. Ltd. Glycerol derivative, device and pharmaceutical composition
US5354853A (en) * 1993-03-12 1994-10-11 Genzyme Corporation Phospholipid-saccharide conjugates
US5965434A (en) * 1994-12-29 1999-10-12 Wolff; Jon A. Amphipathic PH sensitive compounds and delivery systems for delivering biologically active compounds
FR2756565B1 (fr) * 1996-12-04 1998-12-31 Oreal Nouveaux derives d'histidine et leur utilisation en cosmetique ou en pharmacie
JPH11199488A (ja) * 1998-01-09 1999-07-27 Sankyo Co Ltd 抗腫瘍薬のリポソーム化製剤
JPH11217328A (ja) * 1998-01-28 1999-08-10 Nissin Food Prod Co Ltd 抗ｈｉｖ活性を発現する脂質集合体
WO2000030444A1 (en) * 1998-11-25 2000-06-02 Vanderbilt University Cationic liposomes for gene transfer
US7112337B2 (en) 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
AU7868400A (en) * 1999-10-08 2001-04-23 Alza Corporation Neutral-cationic lipid for nucleic acid and drug delivery
DE10109898A1 (de) * 2001-02-21 2002-09-05 Novosom Gmbh Lipide mit veränderlicher Ladung
DE10109897A1 (de) * 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser

Similar Documents

Publication Publication Date Title
US9387262B2 (en) Coated lipid complexes and their use
JP2005517739A5 (enExample)
JP7164547B2 (ja) カチオン性脂質
AU2020328474B2 (en) Lipids for delivery of charged material, formulations thereof and method for making same
KR20210112396A (ko) Rna 전달을 위한 이온화가능한 양이온성 지질
HUT77171A (hu) Lipopoliaminok mint transzfekciós ágensek, és ezeket tartalmazó gyógyászati készítmények
WO2012024233A2 (en) Zwitterionic lipids
CN121698765A (zh) pH敏感性阳离子性脂质、脂质纳米粒子、含有脂质纳米粒子的医药用组合物以及脂质纳米粒子的用途
KR20190021218A (ko) 양이온성 지질
JP2010513354A (ja) トランスフェクションエンハンサー要素を含む脂質および脂質集合体
EP4709710A1 (en) Ionizable cationic lipids for rna delivery
CN119528753A (zh) 含氮链状化合物、制备方法、包含其的组合物和应用
Le Bolc'h et al. Cationic Phosphonolipids as non Viral Vectors
EP3500552A2 (en) Ph-responsive lipids
JP5446119B2 (ja) 低級アシル基含有ポリアミドアミンデンドロン脂質
JP2021178780A (ja) 末端修飾ポリアミドアミンデンドロン脂質
US7368129B1 (en) Amphiphilic materials and liposome formulations thereof
HK40076264A (en) Lipids for delivery of charged material, formulations thereof and method for making same
CN118027129A (zh) 一种可电离脂质化合物及其应用
CN121752256A (zh) 具有核酸负载物和可电离脂质的脂质纳米颗粒